WallStSmart

Axogen Inc (AXGN)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 10513% more annual revenue ($25.27B vs $238.10M). SYK leads profitability with a 13.2% profit margin vs -13.2%. SYK appears more attractively valued with a PEG of 1.43. SYK earns a higher WallStSmart Score of 59/100 (C).

AXGN

Avoid

30

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 0.32

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AXGN.

SYKSignificantly Overvalued (-35.2%)

Margin of Safety

-35.2%

Fair Value

$223.02

Current Price

$305.66

$82.64 premium

UndervaluedFair: $223.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AXGN2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
26.6%8/10

Revenue surging 26.6% year-over-year

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.44B9/10

Large-cap with strong market position

Areas to Watch

AXGN4 concerns · Avg: 3.3/10
Price/BookValuation
9.3x4/10

Trading at 9.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
99.042/10

Expensive relative to growth rate

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
33.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AXGN

The strongest argument for AXGN centers on Debt/Equity, Revenue Growth. Revenue growth of 26.6% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bear Case : AXGN

The primary concerns for AXGN are Price/Book, EPS Growth, Piotroski F-Score.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

AXGN profiles as a growth stock while SYK is a value play — different risk/reward profiles.

AXGN carries more volatility with a beta of 1.17 — expect wider price swings.

AXGN is growing revenue faster at 26.6% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Bottom Line

SYK scores higher overall (59/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Axogen Inc

HEALTHCARE · MEDICAL DEVICES · USA

AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?